Allergy Thera. Regulatory News (AGY)

29 Jan 2008 12:42

Allergy Therapeutics PLC29 January 2008 TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES (1). Identity of the issuer or the underlying issuer of existing shares to whichvoting rights are attached: Allergy Therapeutics PLC 2. Reason for the notification (please tick the appropriate box or boxes) An acquisition or disposal of voting rights: ( X ) An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( ) An event changing the breakdown of voting rights: ( ) Other (please specify) : ( ) 3. Full name of person(s) subject to the notification obligation: Fidelity International Limited (FIL) 4. Full name of shareholder(s) (if different from 3.): See schedule below 5. Date of the transaction and date on which the threshold is crossed or reachedif different): 24 January 2008 6. Date on which issuer notified: 28 January 2008 7. Threshold(s) that is/are crossed or reached: 12% 8. Notified details: A: Voting rights attached to shares Class/type of shares Situation previous to if possible using the the Triggering ISIN CODE transaction Number of shares Number of voting Rights ISINGB00B02LCQ05 8,844,394 8,844,394 Resulting situation after the triggering transaction Class/type of shares Number of shares Number of voting rights % of voting rights if possible using the ISIN CODE Direct Direct Indirect Direct Indirect ISINGB00B02LCQ05 10,624,594 12.96% B: Financial Instruments Resulting situation after the triggering transaction Type of Expiration Date Exercise/Conversion Number of voting % of voting financial Period/ Date rights that may be rights instrument acquired if the instrument is exercised/ converted. Total (A+B) Number of voting rights % of voting rights 10,624,594 12.96% 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: See schedule below Proxy Voting: 10. Name of the proxy holder: Fidelity International Limited (FIL) 11. Number of voting rights proxy holder will cease to hold: 1,780,200 12. Date on which proxy holder will cease to hold voting rights: 24 January 2008 13. Additional information: 14. Contact name: Fabio Correia 15. Contact: fil-regulatoryreporting@uk.fid-intl.com FIL Issuer name: ALLERGY THERAPEUTICS PLC Current ownership percentage: 12.96% Total shares held: 10,624,594 Issued share capital: 81,950,632 SHARES HELD NOMINEE MANAGEMENT COMPANY Fidelity International Limited 145,000 BANK OF NEW YORK BRUSSELS FPM(FIL) is the parent holding 237,533 BROWN BROS HARRIMN LTD LUX FILcompany for various direct and 831,000 JP MORGAN, BOURNEMOUTH FIIindirect subsidiaries, including 784,879 JP MORGAN, BOURNEMOUTH FILFidelity Fund Management Limited 7,337,398 JP MORGAN, BOURNEMOUTH FISL(FFML), Fidelity Investment 640,100 JP MORGAN, BOURNEMOUTH FPMServices Limited (FISL), Fidelity 612,700 NORTHERN TRUST LONDON FPMGestion (FIGEST), Fidelity 35,984 STATE STR BK AND TR CO LNDN (S FPMInvestments Advisory (Korea) Limited(FIAKL), Fidelity Investments Management (Hong Kong) Limited (FIMHK),Fidelity Pension Management (FPM), Fidelity Investments Japan (FIJ) andFidelity Investments International (FII), Investment managers for variousnon-US investment companies and institutional clients. This information is provided by RNS The company news service from the London Stock Exchange